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Alternative splicingDifferential DNA methylation exists in the epigenome of end-stage failing human hearts but whether it contrib-
utes to disease progression is presently unknown. Here, we report that cardiac specific deletion of Dnmt3b, the
predominant DNAmethyltransferase in adultmouse hearts, leads to an accelerated progression to severe systolic
insufficiency and myocardial thinning without a preceding hypertrophic response. This was accompanied by
widespreadmyocardial interstitialfibrosis andmyo-sarcomeric disarray. By targeted candidate gene quantitative
RT-PCR, we discovered an over-activity of cryptic splice sites in the sarcomeric geneMyh7, resulting in a tran-
script with 8 exons missing. Moreover, a region of differential methylation overlies the splice site locus in the
hearts of the cardiac-specific conditional knockout (CKO) mice. Although abundant and complex forms of alterna-
tive splice variants have been reported in diseased hearts and the contribution of each remains to be understood in
further detail, our results demonstrate for the first time that a link may exist between alternative splicing and the
cardiac epigenome. In particular, this gives thenovel evidencewhereby the loss of an epigenomemodifier promotes
the development and progression of heart disease.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Despite remarkable improvements in medical therapy, the prognosis
of patients with cardiac failure remains poor, with almost 50% of patients
dying within 5 year of initial diagnosis. The incidence and prevalence of
cardiac failure is on the rise rapidlyworldwide [1]. Thus, new therapeutic
approaches are urgently needed. Cardiac failure develops often after a
prolonged asymptomatic phase, accompanied by changes in heart mass,
size and shape, a process known as pathological remodelling [2,3]. It is
attributed in some cases to a complex genetic predisposition and/ormul-
tiple environmental factors [4]. Nonetheless, gene expression changes are
often consistent in a failing heart, regardless of the original inciting cause.
Therefore, it would be important to explore whether regulating gene ex-
pression inheart failure could be a therapeutic approach. Onemechanismse 3B leads to progressive heart
stitute, Centre for Translational
9 Singapore.of gene expression regulation that has gained importance is epige-
netics. The epigenome, unlike the genome, undergoes dynamic changes
throughout the course of life. The epigenome, modifiable by diet and
environment, may hence contribute to andmaintain adaptive and devi-
ant gene expression states [5,6]. Globally, the patterns of DNAmethyla-
tion established by de novo DNA methyltransferases DNMT3a and
DNMT3b during embryogenesis are maintained by DNMT1 and remain
stable throughout development and adulthood. However, age, sex and
environmental cardiovascular risk factors have been associated
with specific alteration of DNA methylation at individual loci [7–9].
Genome-wide profiling of DNA methylation in blood from participants
in the Normative Aging study showed that lower LINE-1 methylation in
peripheral blood leukocytes is a predictor of incidence and mortality
from ischemic heart disease and stroke [10]. Experimental animal
models have demonstrated that DNA methylation plays a critical role
in the development of atherosclerosis and cardiovascular disease [8].
In humans,DNMT3Bmutations are causing the rare autosomal recessive
disorder Immunodeficiency, Centromeric instability and Facial anoma-
lies (ICF) Syndrome, associated with severe mental retardation disor-
ders and immunodeficiency [11]. Characterization of the heart has not
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Fig. 1. Cardiac-specific loss of DNMT3B predisposes to cardiomyopathy. (A), Western blotting for DNMT3Bwith mouse whole LV from tamoxifen(tam)-treated Dnmt3b+/+;MerCreMer+
(called “C1”), vehicle-treated Dnmt3b2lox/2lox;MerCreMer+ (called “C2”), and tam-treated Dnmt3b2lox/2lox,MerCreMer+ (called “CKO”). Sarcomeric actin was used to show equal protein
loading. (B), Immunofluorescent histochemistry showedDNMT3B staining (red) in the nuclei of Control hearts; whereas in CKO hearts, loss of stainingwas specifically in cardiomyocytes
(arrowheads), but not in the nuclei of non-cardiomyocytes (arrows). Autofluorescence (green) enabled cardiomyocytes to be recognised by the visualisation ofmyofibrils. Bar represents
10 μm. Echocardiographicmeasurement of (C) interventricular septal and (D) posterior wall dimensions in end-systole and end-diastole (IVSs, IVSd, PWs and PWd respectively) showed
that 2 weeks following transverse aortic constriction (TAC), Control hearts mounted the expected hypertrophic response but this was significantly blunted in CKO hearts. Similarly,
2 weeks post-TAC Control hearts showed compensated and sustained (E) LV internal dimensions in end-systole and end-diastole (LVIDs and LVIDd), and (F) fractional shortening
(%FS),whereas post-TACCKOhearts showeddirect transition to decompensated contractile functionwith significant increase in LVIDs and LVIDd, and decrease in%FS. Notably, CKOhearts
at 2 weeks following Sham surgery alone showed detectable deterioration in systolic function (LVIDs and %FS). Echocardiography was performed with at least N = 10 in each group.
Statistical analysis was performed using Students t-test. *p b 0.05, **p b 0.01, ***p b 0.001. (G), Echocardiography was performed 8 weeks after tam treatment (without TAC) in CKO.
M-mode scan showed distinctive features of LV chamber enlargement (arrows a) and thinning of posterior wall (arrows b) in CKO. Scale: 200 ms and 2 mm. Quantitative dimensions
of hearts 8-weeks post-tam (CKO compared to C1 and C2 control hearts) are displayed in Table 1.
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estingly, Dnmt3b knockout mice die between E13.5 and E16.5 with
cardiac ventricular septal defects amongst others, suggesting that
DNMT3b is necessary for cardiac ventricular septum development and
function [12]. We previously found that the epigenome of end-stage
failing human hearts differ from that of healthy normal controls [13,
14]. This dysregulation of DNA methylation may alter the expression
of genes related to increased disease susceptibility. We therefore set
out to examine whether perturbation to the epigenome contributes to
heart failure development and progression.2. Results
2.1. DNA methyltransferase 3b,(DNMT3b) is the predominant DNA
methyltransferase in the heart
To verify cardiac expression of DNMT3b we used a panel of protein
lysates; mouse tissues, human cell lines and normal human heart. We
determined that the main DNA methyltransferase expressed in human
and mouse hearts is DNMT3B, whereas the other methyltransferases,
DNMT1 and DNMT3A were virtually undetectable (Supplementary
Table 1
Echocardiograhic and LV catheterisation parameters of hearts from Control and CKOmice.
C1: Dnmt3b+/+, MerCreMer+ (tam-treated); C2: Dnmt3b2lox/2lox, MerCreMer+ (vehicle-
treated); CKO:Dnmt3b2lox/2lox,MerCreMer+ (tam-treated). Echo and LV catheterisationwere
performed 8 weeks after administration of Tam or vehicle.
C1 C2 CKO
LVIDd (mm) 4.25 ± .11 4.19 ± .08 4.05 ± .07
LVIDs (mm) 2.88 ± .09 2.91 ± .06 3.20 ± .06**
IVSd (mm) 0.89 ± .06 0.85 ± .02 0.85 ± .03
IVSs (mm) 1.35 ± .07 1.23 ± .04 1.22 ± .04
PWd (mm) 0.80 ± .03 0.75 ± .03 0.77 ± .03
PWs (mm) 1.20 ± .03 1.16 ± .03 1.00 ± .02*
%FS 32.21 ± .99 30.39 ± .97 22.50 ± .76**
HR (beats/min) 527.7 ± 66.4 564.1 ± 53.7 464.7 ± 73
BW (g) 29.3 ± .67 27.9 ± .55 29.2 ± .66
HW (mg) 140.3 ± 4.4 134.7 ± 4.0 138.0 ± 3.1
HW/BW 5.14 ± .13 4.83 ± .14 4.73 ± .07
HW/TL 7.04 ± .17 6.40 ± .22 6.48 ± .14
+dP/dT (mm Hg/s) 9026.3 ± 543.4 8516.6 ± 333.2 3897.3 ± 519.6*
+dP/dT with dobutamine
(mm Hg/s)
10931.5 ± 397.2 11246.2 ± 318.5 6411.9 ± 935.0*
−dP/dT (−mm Hg/s) 7929.6 ± 601.1 7329.5 ± 741.4 6155.7 ± 562.7
−dP/dT with dobutamine
(−mm Hg/s)
8500.7 ± 557.9 8511.8 ± 300.0 3195.5 ± 440.6
177A. Vujic et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 174–183Figs. S1, S2). We therefore proceeded to generate an inducible
cardiac-specific Dnmt3b knockout mouse to explore whether loss of
this methyltransferase specifically in cardiomyocytes, affects cardiac
function.
2.2. Cardiac specific Dnmt3b deletion induced compromised systolic function
in vivo
First, we crossed mice bearing the Dnmt3b2lox/2lox alleles [15] with
transgenic mice that express Cre recombinase in a tamoxifen(tam)-
inducible and cardiomyocyte-specific manner, αMHC-MerCreMer
[16]. We employed 2 sets of control mice Dnmt3b+/+, MerCreMer+
(tam-treated) (we called “C1”) and Dnmt3b2lox/2lox, MerCreMer+ (vehi-
cle-treated) (we called “C2”), and the conditional knockout mouse
Dnmt3b2lox/2lox, MerCreMer+ (tam-treated) (we called “CKO”). Tam
administered over 4 days in 8-week-old adult CKOmice induced approx-
imately 70% reduction in DNMT3B protein levels by week-1 post-tam
(Fig. 1A), but no detectable change in DNMT1 or 3A (Supplementary
Fig. S3). Loss of DNMT3B specifically and only in cardiomyocytes was
also confirmed by immunohisto-chemistry (Fig. 1B). Both sets of control
mice showed normal and indistinguishable cardiac function on echocar-
diography. Dnmt3b2lox/2lox, MerCreMer+ (vehicle-treated) mice (“C2”)
were therefore used as control for subsequent experiments unless other-
wise indicated. We saw no effects of the Dnmt3b deletion on basal LV
function at the immediate stage upon cre-recombinase activation by
tam. We therefore proceeded to subject CKO mice week-1 post-tam and
control mice to myocardial stress by thoracic transverse aortic constric-
tion (TAC). Control mice responded to TAC with the expected robust
level of hypertrophy by 2-weeks post-TAC, with thickened interventricu-
lar septal and left ventricular posterior wall dimensions in both systole
and diastole (IVSs, IVSd and LVPWs, LVPWd respectively) (Figs. 1C, D),
with compensated and sustained contractile function as demonstrated
by unchanged chamber dimensions (LVIDs and LVIDd) and fractional
shortening (%FS) (Figs. 1E, F). Conversely, CKO mice showed a blunted
hypertrophic response (Figs. 1C, D) thatwas accompanied by a significant
increase in LV chamber size and fall in %FS (Figs. 1E, F), indicative of
severely decompensated contractile function. The same was seen in
mice treated with systemic administration of isoprenaline by infusion
pump (Supplementary Table 1), reflecting the consistent outcome of
blunted hypertrophic response and accelerated progression to decom-
pensation resulting from cardiomyocyte loss of DNMT3b regardless of
the form of myocardial stress.Simultaneously, we made the unexpected observation that even
CKO mice that had undergone sham surgery, spontaneously devel-
oped a detectable fall in %FS with an increase in LVIDs but only
after a longer period post-Tamoxifen induction (i.e. 3–4 weeks follow-
ing cre-recombinase activation) (comparison between sham:control
and sham:CKO in Fig. 1F), suggesting that sustained loss of DNMT3B
could itself be leading to compromised systolic function. We therefore
followed up un-operated CKO mice over a longer time course and con-
firmed that 8 weeks following tam-induction alone (without surgery),
CKOmice, but not either set of Control mice, developed significantly re-
duced %FS, increased LVIDs and decreased LVPWs (Table 1), reflecting
that this progression to significant systolic insufficiency was related to
DNMT3b-loss itself. Pressure measurements from LV catheterisation
also corresponded with compromised systolic function in these mice
(Table 1). Both sets of control mice (C1 and C2, as described above)
were used in order to confidently implicate DNMT3b-loss for the pro-
gression to systolic insufficiency.
2.3. Dnmt3b knockout hearts had widespread interstitial fibrosis and
myo-sarcomeric disarray
To explore the mechanism leading to contractile dysfunction in
CKO hearts, we examined LV sections from CKO hearts by histology.
In keeping with the lack of echocardiographic evidence of hypertro-
phy, cardiomyocytes from CKO hearts had unchanged cell widths
(Supplementary Fig. S4). A potential explanatory for myocardial
thinning is an increase in cell death. Therefore to assess if DNMT3B
deletion led to any significant cell loss, we performed TUNEL staining
on heart sections. Exceedingly low levels of TUNEL positive cells were
identified in CKO hearts (b3 per mm3) and even so, these were only
identified in non-cardiomyocytes (Fig. S5). No evidence of cardiomyo-
cyte cell death was detected. Instead widespread interstitial fibrosis
was obvious on Masson's trichrome staining (Fig. 2A) and marked
myo-sarcomeric disarray was evident on electron-micrography (Fig. 2B
and Supplementary Fig. S6).
Foetal gene expression changes are a paradigm formyocardial stress
especially in the context of myocardial hypertrophy. However, in strik-
ing similarity to the lack of a hypertrophic response in CKO compared to
WT-TAC hearts (Supplementary Fig. S4), there were also no significant
changes in foetal gene expression by the same comparisons (Supple-
mentary Fig. S7). On the other hand, we reasoned that in order to
explain the contractile dysfunction in CKO hearts and based on fore-
going histological findings, loss of DNMT3B may lead to altered ex-
pression of pro-fibrogenic or sarcomeric genes. TGF-β signalling
has been implicated in fibroblast activation and myocardial fibrosis
[17,18]. We therefore examined CKO hearts by quantitative RT-PCR
prior to the onset of interstitial fibrosis (before week-8), but did
not find any differential expression of genes in the TGF-β signalling
pathway (not shown). This contradicted the possibility that the pri-
mary defect in CKO hearts is mediated by an early TGF-β dependent
mechanism. We further checked transcript abundance of various
sarcomeric genes including Mybpc3, Tnnt2 and Tnni3, and similarly
did not find any overall differential expression of these genes (not
shown). Instead we noticed on quantitative RT-PCR of Myh7 that
amplicons targeting specifically only certain exons of the Myh7
gene showed differential transcript levels between CKO and control
hearts.
2.4. Sarcomeric gene Myh7 was alternatively spliced in the CKO
We examined Myh7 transcripts more closely and discovered an
over-activity of cryptic splice sites within exons 13, 26 and 28 in CKO
hearts (Figs. 3A, B). Complex alternative splicing ofMYH7 has been de-
scribed in human cardiomyopathy [19]. We looked but did not find any
differential levels in splicing variants of other sarcomeric genes (Myh6,
Mybpc3, Tnnt2 and Tnni3), and hence focussed our attention onMyh7.
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Fig. 2. (A), Masson's trichrome staining showed significant and widespread interstitial fibrosis (blue) which was quantified as %area of each histological section. Black bar represents
100 μm. Three sectionswere examined for each of 5 hearts in each group. Students t-test, *** p b 0.001. (B), Electronmicrographs of cardiomyocyte nuclei in CKO hearts showed significant
myo-sarcomeric disarray. White bars represent 500 nm. Supplementary Fig. S6 shows further examples of electron micrographs.
Fig. 3. CKO hearts showed increased levels ofMyh7 alternative splicing. (A), shows the exon-intron structure ofMyh7 from exon 13 to exon 29, and novel cryptic splice sites. White boxes
indicate exons missing in the alternatively spliced transcript (AST). Orange boxes indicate stretches of intronic sequence that are incorporated into the AST. Arrows indicate positions of
Forward (F) and Reverse (R) primers used to amplify the cryptic splice sites in (B). (B), Cryptic splice siteswere amplified using primer pairs F13-R28 and F26-R28. F28-R29was used as a
positive control primer pair. PCR products were visualised on a 2% agarose gel and showed that cryptic spliced junctions could be amplified in all hearts but more abundantly in CKO.
Negative control “minus RT” showed an absence of PCRproducts. (C), PCR products from(B)were sequenced, aligned to themouse reference genome and proven to be novel cryptic splice
sites. (D), Shows the positions of primer-probe pairs used for quantitative RT-PCR for amplicons 1 to 4. Sequences of primers and probes are listed in Supplementary Tables 2 and 3. (E–H),
Relative quantities of amplicons 1 to 4 were normalised to total Myh7 transcripts. Total Myh7 transcript abundance did not differ between groups (not shown). PCR were
performed in triplicate and at least N = 8 were used for each group. Statistical analysis was performed by Students t-test, **p b 0.01, ***p b 0.001. (I), Immunofluorescent
histochemistry using anti-MYH7 antibody labelled perinuclear aggregates (arrows) that co-localised with Ubiquitin in CKO, but not Control hearts. Bar represents 10 μm. See
Supplementary Fig. S10 for further examples. (J), Vertical bars across the exon–intron structure ofMyh7 indicates individual CpGs. %Methylation for each CpG within clusters 1 to 4
was measured by pyrosequencing using gDNA from Control (blue) and CKO (red) hearts. Sequencing was performed in 5 technical replicates and at least N= 5 hearts were used in each
group. Statistical analysis was performed by Students t-test. *p b 0.05, **p b 0.01.
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179A. Vujic et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 174–183In CKO hearts, we performed strand-specific RT-PCR forMyh7 and PCR
products containing the cryptic splice junctions were verified by se-
quencing (Figs. 3B, C). Next, we designed specific primer-probe sets
for RT-PCR to quantify the abundance of either alternative spliced tran-
script (AST) only (Fig. 3D, amplicons 1, 2), wild type Myh7 transcriptC1 C2 CKO
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180 A. Vujic et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 174–183the cryptic splice sites in CKO hearts. We returned to CKO hearts that
underwent surgical TAC and verified that the abundance of AST was
again substantially higher in CKO hearts that underwent TAC, than
control (Supplementary Fig. S8). More notably, control hearts that
underwent TAC did not show significant increase in AST in relationto wild-type Myh7 transcripts, indicating that myocardial stress
alone was not sufficient to switch usage to these cryptic splice
sites, and also implying that AST and the switch to cryptic splice
usage is not merely secondary to myocardial stress but a result of
the loss of DNMT3B.
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ubiquitin-related degradation
Alignment of the AST predicts that it lacks 8 exons and generates a
premature termination codon. Quantifiable abundance of AST in CKO
hearts however suggests that to some extent, some of this transcript
escaped nonsense mediated decay. Indeed, if translated, the AST may
encode a 47 kDa peptide missing many key C-terminal domains of
MYH7. We therefore probed whole cardiac protein lysates from CKO
and control hearts using an anti-MYH7 antibody, and found that there
were additional immunoreactive bands in the Western blot for CKO
hearts corresponding to the ~40–50 kDa molecular weight (Supple-
mentary Fig. S9). Interestingly, anti-MYH7 antibody also labelled
perinuclear aggregates that co-localisedwith ubiquitin (Fig. 3I, and Sup-
plementary Fig. S10), suggesting that CKO hearts may contain MYH7
immunoreactive proteins that were targeted for ubiquitin-related
degradation.
Accumulation of aggregates may represent defective and ubiquitin-
labelled proteins that are resistant to degradation in CKOor that emerging
cardiomyopathy itself resulted in inefficient processing of protein deg-
radation. To test the in vitro expression of AST in cardiomyocytes, we
generated both wild-type and AST FLAG-tagged constructs of Myh7
(FLAG-Myh7-WT and FLAG-Myh7-AST) (Supplementary Fig. S11).
Unlike FLAG-MYH7-WT that followed an expected sarcomeric distri-
bution when overexpressed in neonatal rat cardiomyocytes, FLAG-
MYH7-AST formed perinuclear aggregates (Fig. 3J, and Supplementary
Fig. S12), consistent with our observation in CKO-hearts. Overexpressionof either construct did not lead to differential levels of cardiomyocyte
apoptosis (not shown). We could not explain immunoreactivity of our
FLAG antibody observed in the nucleus, but this may imply sarcomeric
protein presence in the nucleus as observed previously for troponin
[31], and here made more prominent by overexpression. Nuclear immu-
noreactivity was consistent with both FLAG-Myh7-WT and FLAG-Myh7-
AST constructs, but the striking difference remained that AST resulted
in perinuclear aggregates, compared to a sarcomeric distribution of the
WT construct.
Mechanisms of alternative splicing in the heart have previously impli-
cated the role of specific splicing factors (ASF/SF2 and CUGBP1) [20–22].
We checked but did not find any difference in the protein abundance of
these splicing factors in CKO hearts (Supplementary Fig. S11).2.6. Differential methylation overlays the alternatively spliced Myh7
transcript
Finally we assessed the effect of DNMT3B loss on the DNA methyla-
tion profile at theMyh7 locus in CKO and control hearts. We inspected
theMyh7 genomic sequence and noticed that a CpG-rich locus overlies
the site of alternative splicing. We proceeded to assay for differential
DNA methylation of each of the series of cytosine nucleotides within
this locus by pyrosequencing. Remarkably, contrary to the exact same
methylation profiles between control and CKO in other cystosines at
the locus,methylation of 3 cytosines (CpGs)within intron 27were signif-
icantly different (Fig. 3K).
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Epigenetic modifications, such as DNA methylation and histone
modifications, represent attractive disease mechanisms because they
might help to explain how environmental and lifestyle factors can
impose aberrant gene expression patterns in an individual's lifetime
that can result in increased cardiovascular risk. Herein we report that
deletion of a de novo DNA methyltransferase, DNMT3B, in the adult
mouse heart correlatedwith alternative splicing of the important sarco-
meric geneMyh7, myosarcomeric disarray and an onset of cardiomyop-
athy. The loss or inactivation of DNMT3B may not directly represent
disease mechanism in human heart failure, but we have utilised this
model as proof of concept that loss of the de novo methyltransferase
resulted in methylation change in at least one cardiac-relevant locus
which we have tested. Indeed in our hands, DNMT3B protein levels
were not significantly altered in human cardiomyopathic hearts com-
pared to healthy control (data not shown). Hence, instead we have
utilised this experimental mouse model to demonstrate that perturba-
tion of DNA methyltransferase in the heart led to accelerated heart
failure. Specifically, our data correlates a change in the epigenome over-
lying an over-activity of cryptic splice sites withinMyh7, in CKO hearts,
and an accumulation of alternatively spliced transcripts and possible
truncated protein products in the heartwith emergent contractile insuf-
ficiency. The latter fits well with existing data showing that other
chromatin structures such as histone modification [23] and DNA factor
binding-mediated pausing of RNA polymerase II [24] regulate alter-
native splicing in other specific contexts. This study implies that, as
in neurons that are the other archetypal non-dividing cells, dynamic
methylation states may also exist in terminally differentiated adult
cardiomyocytes. Crystal co-structure analysis of DNMT1 with oligo-
nucleotides containing CpGs suggests that unmethylated CpGs are
not accessible to the DNMT1 active site unless CpGs are hemi-
methylated [25]. For non-dividing cells that undergo dynamic turn-
over of methylation and de-methylation, without prior requirement
for hemi-methylated CpGs, the DNMT3A and DNMT3B are therefore
likely to be the crucial DNA methyltransferases. The increase in DNA
methylation observed at the cryptic splice sites within Myh7, in CKO
is surprising given that patients with loss of DNMT3b activity exhibit
hypomethylation of pericentromeric regions and selective demeth-
ylation of promoters associated with altered gene expression [26].
Since DNMT3A was not upregulated upon DNMT3b deletion it likely
that there is anothermechanism that induces locus specificmethylation
increase following the loss of DNMT3B. In concordance with our previ-
ous studies that showed that end-stage cardiomyopathic human hearts
have significantly more hypomethylated CGIs and gene promoters than
healthy control hearts [14], this data supports that a re-distribution
in methylation patterns, rather than a loss of global methylation
is the difference between a healthy and cardiomyopathic heart, even if
the initiating cause is loss of a DNA methyltransferase. The mechanism
for locus-specific increasedmethylationwill require further elucidation.
Significant evidence has suggested a close relation between patho-
physiology of heart failure and increased oxidative stress and DNA
damage [27–29]. The precise contribution of alternatively spliced
transcripts to heart disease progression is likely to be context-specific,
and although diseased hearts are now known to have a significant,
varied and complex accumulation of alternatively spliced transcripts,
the contribution of each to disease progression will need further study
[19,30]. Our results here however provide the first hint that RNA splic-
ing in the heart can be affected by the epigenome. If the cardiac epige-
nome is dynamic and subject to external factors, it could potentially
have a far-reaching role in cardiac failure disease development and
progression.
4. Methods
See supplementary materials.Disclosures
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